Autoimmune Encephalitis

Amritpal Anand; Chichun Sun

Autoimmune Encephalitis

Author: Amritpal Anand Editor: Chichun E. Sun Updated: 7/5/2026 11:11:38 PM

Introduction

Autoimmune encephalitis is an immune-mediated condition that causes central nervous system (CNS) inflammation and is one of the most common causes of noninfectious encephalitis. In the past decade, autoimmune encephalitis has emerged as a differential diagnosis when a classic infection cannot explain focal neurological symptoms. Although the exact mechanism of autoimmune encephalitis is unknown, results from studies suggest that autoimmune antibodies target CNS proteins, leading to widespread inflammation.[1]

Autoimmune encephalitis commonly presents with new-onset acute to subacute neurologic symptoms, including encephalopathy, behavioral changes, psychosis, and seizures. Clinical symptoms develop over a few weeks to 3 months. Autoimmune encephalitis involves several parts of the nervous system, including the limbic system, the spinal cord, and the entire neuraxis. Autoimmune encephalitis can be confirmed by multiple modalities, including laboratory testing (antibody detection in serum and cerebrospinal fluid [CSF]), neuroimaging, and electroencephalography. Antibody-negative autoimmune encephalititis can occur when the patient's clinical presentation is consistent with autoimmune encephalititis, but no identifiable autoantibodies are found.

Autoimmune encephalitis can also be associated with underlying malignant neoplasms. Therefore, once the diagnosis is established, patients should undergo cancer screening because of the high degree of association with underlying malignant neoplasms. Clinicians should initiate treatment early when clinical suspicion for autoimmune encephalitis is high because patients often respond and achieve significantly improved outcomes. The current review describes the current state of knowledge on various types of autoimmune encephalititis and provides a concise, up-to-date summary.

Etiology

Register For Free And Read The Full Article

Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed. Earn CME/CE by searching and reading articles.

Search engine and full access to all medical articles
10 free questions in your specialty
Free CME/CE Activities

Free daily question in your email
Save favorite articles to your dashboard
Emails offering discounts

Learn more about a Subscription to StatPearls Point-of-Care

Etiology

Although the exact mechanism remains under investigation, autoimmune encephalitis is thought to involve an exaggerated immune response to neuronal self-antigens. Unlike paraneoplastic encephalitis, which is a T-cell-mediated response, antibodies in autoimmune encephalitis are intrinsically pathogenic. These antibodies induce inflammation by targeting specific neuronal proteins. When bound to target proteins, these antibodies induce conformational changes that lead to an inflammatory response. Forms of autoimmune encephalitis associated with cell-surface antigens respond to immunotherapy and tend to affect the limbic system. Conversely, forms of autoimmune encephalitis associated with intracellular antigens respond poorly to immunosuppression and tend to cause widespread inflammation.[1]

Epidemiology

Results from a population-based study from Olmsted County, Minnesota, found the incidence of autoimmune encephalitis to be approximately 0.8 to 1.2 per 100,000 person-years, with a prevalence of 13.7 per 100,000, comparable with infectious encephalitis (11.6 per 100,000). The incidence has increased over time (from 0.4 per 100,000 in 1995 to 2005 to 1.2 per 100,000 in 2006 to 2015), attributable to improved detection.[2] Anti–N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis now surpasses any individual viral cause of encephalitis in young persons. Anti–NMDAR and anti–leucine-rich glioma-inactivated 1 encephalitis (anti-LGI-1) are the 2 most common forms of autoimmune encephalitis.

Pathophysiology

To date, the exact mechanism of immune tolerance collapse in autoimmune encephalitis remains largely unknown. Patients with autoimmune encephalitis often have an infection as a preceding event, causing inflammation that leads to neurological symptoms. Results from case reports and observational studies suggest that herpes simplex virus encephalitis triggers an immune response, causing anti-NMDAR encephalitis.[3] Additionally, genetic factors such as human leukocyte antigen (HLA) were strongly associated with certain antibody production, causing autoimmune responses, eg, immunoglobulin-like cell adhesion molecule 5 antibody encephalitis.[4] Table 1 summarizes the most commonly reported forms of autoimmune encephalitis.[5]

Table 1. Commonly Reported Autoimmune Encephalitis

Auto-antibody	Median age of onset	Male to female ratio	Clinical manifestations	Associated malignant neoplasms	Response to therapy
NMDAR	21 (2 mo-85 y)	1:4	Prominent neuropsychiatric manifestations Seizures Movement disorders Language disorders Autonomic dysfunction Central apnea Coma	Ovarian teratoma	Approximately 53% reported improvement within the first 4 weeks from first-line therapy or tumor removal Approximately 80% achieved good outcomes at 24 months with mRS 0-2 Approximately 10% of relapses occurred within 2 years Reduced if treated with immunotherapy or tumor removal 5%-7% mortality [6][7]
LGI-1	64 y (31-84 y)	2:1	Fasciobrachial dystonic seizures Hyponatremia Limbic encephalitis	Rarely associated with tumors, but when present: thymoma, small cell lung carcinoma, breast cancer, thyroid cancer, and lymphoma	80% response to immunotherapy Mild cognitive defect at 2-year follow-up Relapses are common (35%)[8][9]
CASPR2 (IGG4)	66 y (25-77 y)	9:1	Limbic encephalitis Morvan syndrome Peripheral nerve hyperexcitability Autonomic dysfunction Neuropathic pain Cerebellar dysfunction	Thymoma	Approximately 48% had full/good recovery with immunotherapy or tumor removal Approximately 44% had partial recovery with immunotherapy Approximately 25%-30% had relapses Case fatality rate was 10% after 2 years [10][11]
GABA-A (IgG1)	40 y (2.5 mo-88 y)	1:1	Diffuse encephalitis Seizures, frequent status epilepticus	Thymoma	Substantial improvement (86%), although mortality with status epilepticus was reported [12][13]
GABA-B (IgG1)	61 y (16-77 y)	1.5:1	Limbic encephalitis Seizures Ataxia Orolingual movements	Small-cell lung carcinoma, neuroendocrine tumors	Neurological response with immunotherapy and cancer treatment (90%) [14]
AMPA	53.1 y (14-92 y)	2:1	Limbic encephalitis Confusion Amnesia Seizures Psychiatric symptoms	Thymus, small cell lung cancer, breast, and ovarian cancers	Good response to immunotherapy 16% died from complications related to underlying neoplasm [15]
DPPX (IgG4)	53 y (13-75 y)	1.5:1	Multifocal encephalitis Amnesia Delirium Myoclonus, tremor, hyperekplexia (exaggerated startle reflex) Prominent diarrhea and weight loss	B-cell neoplasm (gastrointestinal tract lymphoma and CLL)	Approximately 63% responsive to immunotherapy [16]
Glycine	50 y (1-75 y)	1:1	Stiff person syndrome PERM Limbic encephalitis	Thymoma, B-cell lymphoma	Good response to immunotherapy, with a median mRS score of 1 at the most recent follow-up 29% associated with autoimmune disorders (psoriasis, thyroid, diabetes)[17] 10% mortality
MOG (IgG1)	37 y (1-74 y)	1:1	Optic neuritis Myelitis Seizures Encephalitis, including FLAMES		80% have a good response to corticosteroids Relapses are common [18]
Neurexin	44 y (23–57 y)	1:2	Prodromal fever Weight loss Gastrointestinal symptoms Confusion Seizures Decreased level of consciousness		Partial response to immunotherapy (60%) [19]
IgLON5 (IgG1/4)	64 y (46-83 y)	1:1	Sleep disorder (REM and non-REM parasomnia, sleep apnea) Bulbar dysfunction PSP-like syndrome HLA-DRB110:01/HLADQB**05:01 alleles in 87%		43% respond better with combination therapy vs monotherapy (67% vs 32%) Better response with second-line compared to first-line therapy (54% vs 33%)[4][20]
GluK2	Limited data (small cohort)	Not established	Encephalitis with prominent cerebellar involvement/cerebellitis Obstructive hydrocephalus Involuntary movements Emotional dysregulation	Multiple myeloma [21]	Antibody effects were reversible in vitro Symptom resolution was reported with immunotherapy and tumor-directed therapy Insufficient data were available for response rates [22]
ADAM23	Limited data (single case: 71 y)	Not established	Rapidly progressive memory loss Psychobehavioral abnormalities Impaired consciousness and seizures may occur post-HSE CSF shows lymphocytic inflammation with neutrophil pattern	None identified (single case)	Limited response to IVIG alone Improvement with high-dose methylprednisolone; predominantly IgG4 subclass [23][24]
GFAP	46 y (1-103 y)[25]	1.5:1	Subacute meningoencephalomyelitis (85%) Headache, fever, encephalopathy; Cerebellar dysfunction (57%); myelitis (30%-49%); Optic neuritis/papillitis (35%); movement disorders; seizures; autonomic dysfunction; Characteristic MRI findings: linear perivascular radial enhancement; prodromal infection common (45%-82%)[26]	Ovarian teratoma Adenocarcinomas Breast/ovarian carcinoma Thymoma Melanoma Myeloma	Excellent corticosteroid response (83%-89%); monophasic course in 81%-83% Good outcome (mRS ≤ 2) in 89% Relapses in 20%-30% [27] Children have better prognosis than adults [28]

Abbreviations: ADAM23, ADAM metallopeptidase domain 23; AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; CASPR2, contactin-associated protein-like 2; CLL, chronic lymphocytic leukemia; CSF, cerebrospinal fluid; DPPX, dipeptidyl-peptidase-like protein 6; FLAIR, fluid-attenuated inversion recovery; FLAMES, FLAIR-hyperintense lesions in anti-MOG-associated encephalitis with seizures; GABA, γ-aminobutyric acid; GFAP, glial fibrillary acidic protein; GluK2, glutamate kainate receptor 2; HLA, human leukocyte antigen; HSE, herpes simplex virus encephalitis; IgG, immunoglobulin G; IgLON5, immunoglobulin-like cell adhesion molecule 5; IVIG, intravenous immunoglobulin; LGI1, leucine-rich glioma-inactivated 1; MOG, myelin oligodendrocyte glycoprotein; MRI, magnetic resonance imaging; mRS, modified Rankin Scale; NMDAR, N-methyl-D-aspartate receptor; PERM, progressive encephalopathy with rigidity and myoclonus; PSP, progressive supranuclear palsy; REM, rapid eye movement.

History and Physical

The initial clinical presentation is often vague and nonspecific. Thus, if the clinician has a sufficient index of suspicion, the diagnostic evaluation should be initiated, including multiple modalities such as imaging, serology, CSF analysis, and electroencephalography (EEG). The presentation varies from typical limbic system involvement to syndromes with complex neuropsychiatric manifestations. Certain forms of autoimmune encephalitis have specific clinical syndromes.

Approximately 70% of patients have prodromal manifestations, including headache, fever, and viral-illness–like symptoms. Clinical presentation involves an acute to subacute onset of memory deficits, altered mental status, behavior changes, psychosis, orofacial dyskinesia, hallucinations, agitation, delusions, catatonia, seizures, or abnormal movements. Patients with autoimmune encephalitis may have a fluctuating clinical course with interval improvement.[29] Psychiatric manifestations can make diagnosis difficult.

Patients might develop a decreased level of consciousness or central hypoventilation requiring mechanical ventilation. Review of systems should include questions about fever, weight loss, night sweats (B symptoms), and oncologic history. A complete neurological examination is vital to evaluate for focal neurological deficits and rule out other possible causes of encephalitis.

Evaluation

Diagnosing autoimmune encephalitis can be difficult because the average time from symptom onset to diagnosis often takes a few weeks to 3 months. Infectious encephalitis can be fatal and should always be excluded from the differential diagnosis before considering autoimmune encephalitis. Even after eliminating other potential causes, diagnosing autoimmune encephalitis can be difficult. Diagnosing autoimmune encephalitis requires multiple diagnostic tools and clinical judgment, including assessment for various neuropsychiatric symptoms, laboratory tests, neuroimaging, and electroencephalography. Therefore, a group of experts generated consensus diagnostic criteria to help clinicians diagnose autoimmune encephalitis. The following criteria were adopted for the evaluation of a possible diagnosis of autoimmune encephalitis:

Subacute onset (usually within a few weeks but less than 3 months) with a change in the level of consciousness or personality; limbic system involvement, including working memory deficits, lethargy, or psychiatric manifestations. At least 1 of the following:
- New focal clinical central nervous system findings
- Seizures not explained by a previously diagnosed seizure disorder
- Cerebrospinal fluid pleocytosis (> 5 white blood cells per mm³)
- Brain MRI findings suggestive of encephalitis
Reasonable exclusion of possible alternative causes*[30]

All 3 criteria must be met. Brain MRI findings include increased signal on T2-weighted fluid-attenuated inversion recovery (FLAIR) sequence images seen in one or both medial temporal lobes (limbic encephalitis) or multifocal areas involving gray or white matter compatible with demyelination or inflammation.

Definite Diagnosis of Autoimmune Limbic Encephalitis

Subacute onset of symptoms (< 3 months) involving the limbic system (memory deficits, neuropsychiatric symptoms, or seizures)

MRI brain findings are suggestive of an abnormality highly restricted to the bilateral medial temporal lobes on T2-weighted FLAIR images
One of the following is present:
- CSF pleocytosis (> 5 white blood cells per mm³)
- Electroencephalography findings are suggestive of slow-wave or epileptic activity corresponding to the temporal lobes
Reasonable exclusion of alternative causes*

*Possible causes include infectious meningoencephalitis, septic encephalopathy, metabolic encephalopathy, toxins, cerebrovascular disease, neoplasms, Creutzfeldt-Jakob disease, epileptic disorders, Hashimoto encephalopathy, autoimmune disorders, mitochondrial or metabolic storage disorders.

Both serum and cerebrospinal fluid testing are recommended. In general, cerebrospinal fluid testing is more sensitive and specific for most neuronal cell-surface antibodies, except for anti–leucine-rich glioma-inactivated 1 (LGI1) and anti–contactin-associated protein-like 2 (CASPR2), which are more sensitive in the serum. If initial testing for both serum and cerebrospinal fluid is not feasible, experts recommend testing for the following in serum: leucine-rich glioma-inactivated 1 (LGI1), glutamic acid decarboxylase 65 (GAD65), immunoglobulin-like cell adhesion molecule 5 (IgLON5), glycine receptor (GlyR), voltage-gated calcium channel (VGCC); the following in cerebrospinal fluid: N-methyl-D-aspartate receptor (NMDAR), glial fibrillary acidic protein (GFAP), Kelch-like protein 11 (KLHL11); and the following in both serum and cerebrospinal fluid: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA), dipeptidyl-peptidase-like protein 6 (DPPX), contactin-associated protein-like 2 (CASPR2), and γ-aminobutyric acid B receptor (GABA-B).[31]

If all 4 criteria are met, a definitive diagnosis can be made. If 1 of the first 3 criteria does not match, a diagnosis of definite limbic encephalitis can be made only in the presence of antibodies against cell-surface, synaptic, or onconeural proteins. Antibodies should be detected both in serum and CSF for diagnosis.

Antibody testing methods also affect the accuracy of results. Complementary assays (eg, live- or fixed-cell-based assays with adjunctive immunohistochemical tissue-based assays) have lower false-positive rates than single-assay methods. Live cell-based assays use native antigen and therefore are more likely to yield meaningful results than fixed assays.[5] Following diagnosis, screening for malignant neoplasms is necessary. Coexisting malignant neoplasms correlate with the clinical subtype of autoimmune encephalitis. The best initial step is to perform a CT scan of the chest, abdomen, and pelvis to look for pulmonary, abdominal, or urogenital malignant neoplasms. Women should undergo gynecological examinations with breast and ovarian ultrasonography or MRI based on sensitivity and clinical judgment. Similarly, men should undergo testicular ultrasonography as part of the urological evaluation. If the above imaging does not yield any findings, a whole-body 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) should be considered.

Treatment / Management

The treatment options for autoimmune encephalitis include immunosuppression and, if applicable, tumor resection. The treatment regimen is based on principles of autoimmune disease treatment, with the aim of depleting pathogenic antibodies. Clinicians should not delay treatment until antibody detection because early initiation is associated with improved outcomes. An interdisciplinary team, including autoimmune neurologists, rheumatologists, and oncologists, should be involved in treating autoimmune encephalitis.

Results from expert consensus data showed that 84% of specialists select corticosteroids alone or in combination with intravenous immunoglobulin (IVIG) or plasmapheresis as first-line therapy. Dosing for corticosteroids is 1 g of intravenous methylprednisolone for 3 to 5 days, IVIG at 0.4 g/kg/d for 5 days, and plasmapheresis alone or in combination.[32] Corticosteroids are often the initial treatment, are frequently combined with either IVIG or plasma exchange, and are considered first-line therapies.[5] Plasmapheresis should be considered when patients have severe dysautonomia, refractory seizures, or central hypoventilation syndrome.

Second-line immunotherapy can be initiated with or after first-line therapy when patients do not improve with first-line regimens. Rituximab is now the preferred second-line agent, chosen by 80% of experts, compared with cyclophosphamide (10%). Results from a survival analysis demonstrated that rituximab use was associated with a 71% lower hazard of time to first relapse (HR, 0.29; 95% CI, 0.09-0.85).[33]. Rituximab (375 mg/m² for 4 weeks) is also the most popular maintenance therapy (46% of experts).[34] Cyclophosphamide (750 mg/m² for 6 months) may be used alone or combined in the adult population. In anti-NMDAR receptor encephalitis, combining first- and second-line therapies reduces morbidity and mortality, but second-line agents are rarely needed in anti-LRG1 autoimmune encephalitis.[35][36](A1)

Third-Line and Refractory Therapy

Approximately 10% of patients are refractory to first- and second-line therapies.[37] Options for refractory cases include:

Tocilizumab (IL-6 receptor antagonist): Results from small retrospective studies suggested better outcomes at 24 months compared with continued rituximab in treatment-refractory cases
Bortezomib (proteasome inhibitor): Plasma cell–depleting agent with mixed evidence
Daratumumab (anti-CD38): Emerging plasma cell–depleting agent
Other emerging therapies: Intrathecal methotrexate, natalizumab, low-dose IL-2, anakinra, and tofacitinib [38][39]

However, if an underlying malignant neoplasm is found, the patient should undergo tumor resection or chemotherapy because treatment accelerates improvement and prevents relapses.[7](B2)

Differential Diagnosis

Because of its variable presentation, autoimmune encephalitis can mimic other conditions. Most patients develop additional syndromic features within days or weeks. Because of the initial prodrome of fever and headache, infectious causes of meningoencephalitis must be ruled out. Cognitive and behavioral changes should prompt a diagnostic evaluation for toxic, metabolic, oncologic, and neurodegenerative causes, including rapidly progressive dementia. Focal neurological deficits should prompt evaluation for stroke and seizures. Patients must undergo a thorough physical examination, along with neuroimaging and laboratory testing, for diagnosis.[40]

Some autoimmune encephalitides have early and prominent psychiatric manifestations (eg, anti-NMDA receptor encephalititis), leading to admission to an inpatient psychiatric unit. Clinicians should focus on the disease's clinical progression, as these patients develop additional features of the syndrome within days to a few weeks. Careful examination may reveal subtle neurologic deficits that serve as clues to autoimmune encephalitis. Patients may present with a demyelinating disorder (eg, multiple sclerosis) or autoimmune disease (eg, lupus or neurosarcoidosis) that has multisystem involvement and should be appropriately evaluated with cerebrospinal fluid studies and neuroimaging. Neurodegenerative diseases such as Alzheimer disease usually have a chronic course and should be further evaluated with neuroimaging, although they rarely can present as rapidly progressive dementia. Rarely, inherited and metabolic disorders can cause neuropsychiatric manifestations with a positive family history that require further study.

Prognosis

As noted above, autoimmune encephalitis usually responds to immunosuppression and tumor removal, although staging of the cancer is independently associated with adverse outcomes. Results from an observational cohort study showed that 94% of patients received first-line therapy with immunosuppression or tumor removal, resulting in improvement within 4 weeks (53%), with most patients having good outcomes in the first 24 months. Outcomes continue to improve up to 18 months from symptom onset. Predictors of good outcomes included early treatment and no requirement for intensive care unit admission.[7]

Long-Term Outcomes

Cognitive recovery may continue for up to 3 years after diagnosis, with the most improvement in the first 6 months.[41] However, beyond 36 months:

34% of patients have persistent cognitive impairment (z-score of −1.5 standard deviations), and 65% score below average in at least 1 cognitive domain, despite favorable modified Rankin Scale (mRS) scores (≤ 2) in 91% of patients. [41]
Memory and language are the most affected domains in the long term.[42]
The mRS does not fully capture outcomes because cognitive deficits, emotional well-being, social functioning, and energy levels can be impaired even with favorable scores.[43][44]
30% of patients do not resume school or work, and 18% require accommodations.[42]
Predictors of poor cognitive outcome include delayed treatment, higher disease severity, and longer duration of the acute phase.[42]

Patients need to be monitored closely after recovery to evaluate for relapse. Recommendations suggest surveillance imaging at 4- to 6-month intervals for at least 4 years. Overall, cell-surface antibodies are associated with a better prognosis than intracellular antibodies.

Complications

Although autoimmune encephalitis is often responsive to treatment, delayed or absent treatment can lead to serious complications. Complications include cognitive impairment, sleep disorders, hyperkinesia, autonomic dysfunction, persistent amnesia (anti–leucine-rich glioma-inactivated 1 encephalitis), coma, and status epilepticus. Results from a retrospective study by Xu et al found that central hypoventilation syndrome is a key risk factor for mechanical ventilation during hospitalization in patients with anti–NMDAR encephalitis and requires close monitoring.[45]

Deterrence and Patient Education

Patient education is necessary to understand the condition's etiology, onset, and progression; its strong association with underlying malignant neoplasms; treatment; and prognosis. Patients should be educated about the variable course of the disease, which may lead to a delay in diagnosis. Furthermore, patients should be encouraged to follow up with their neurologist or oncologist after hospital discharge due to concerns about relapse and screening for malignant neoplasms.

Patients with autoimmune encephalitis should undergo imaging every 6 months for at least 4 years to look for any tumor growth or metastasis, which might not be evident early and can lead to neurological manifestations. Families should be involved in clinical interviews whenever possible, because they may notice unusual changes in the patient's behavior or possible seizures. Moreover, patients should be educated about the adverse effects of chronic therapy with corticosteroids and the role of immunosuppressive treatment, which may put them at risk of infection or systemic adverse effects.

Enhancing Healthcare Team Outcomes

A variable clinical presentation encompasses autoimmune encephalitis with varying disease progression levels that require the expertise of multiple specialists. Clinicians involved in the treatment of autoimmune encephalitis need to be well informed about the condition to ensure the patient receives the most appropriate care. The treatment of autoimmune encephalitis is complex and requires expert opinion from a neurologist, rheumatologist, internist, an oncologist, surgical oncologist, and pharmacist, all functioning as a cohesive, interprofessional team. Long-term follow-up is essential, even after full recovery, because of the potential for relapse, adverse effects of immunotherapy, and tumor screening secondary to autoimmune encephalitis. With proper treatment, the patient should be able to make a full recovery and maintain remission.

References

[1]

Hébert J, Muccilli A, Wennberg RA, Tang-Wai DF. Autoimmune Encephalitis and Autoantibodies: A Review of Clinical Implications. The journal of applied laboratory medicine. 2022 Jan 5:7(1):81-98. doi: 10.1093/jalm/jfab102. Epub [PubMed PMID: 34996085]

[2]

Dubey D, Pittock SJ, Kelly CR, McKeon A, Lopez-Chiriboga AS, Lennon VA, Gadoth A, Smith CY, Bryant SC, Klein CJ, Aksamit AJ, Toledano M, Boeve BF, Tillema JM, Flanagan EP. Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. Annals of neurology. 2018 Jan:83(1):166-177. doi: 10.1002/ana.25131. Epub [PubMed PMID: 29293273]

[3]

Armangue T, Spatola M, Vlagea A, Mattozzi S, Cárceles-Cordon M, Martinez-Heras E, Llufriu S, Muchart J, Erro ME, Abraira L, Moris G, Monros-Giménez L, Corral-Corral Í, Montejo C, Toledo M, Bataller L, Secondi G, Ariño H, Martínez-Hernández E, Juan M, Marcos MA, Alsina L, Saiz A, Rosenfeld MR, Graus F, Dalmau J, Spanish Herpes Simplex Encephalitis Study Group. Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. The Lancet. Neurology. 2018 Sep:17(9):760-772. doi: 10.1016/S1474-4422(18)30244-8. Epub 2018 Jul 23 [PubMed PMID: 30049614]

Level 2 (mid-level) evidence

[4]

Cabezudo-García P, Mena-Vázquez N, Estivill Torrús G, Serrano-Castro P. Response to immunotherapy in anti-IgLON5 disease: A systematic review. Acta neurologica Scandinavica. 2020 Apr:141(4):263-270. doi: 10.1111/ane.13207. Epub 2020 Jan 12 [PubMed PMID: 31853949]

Level 1 (high-level) evidence

[5]

Irani SR. Autoimmune Encephalitis. Continuum (Minneapolis, Minn.). 2024 Aug 1:30(4):995-1020. doi: 10.1212/CON.0000000000001448. Epub [PubMed PMID: 39088286]

[6]

Al-Diwani A, Handel A, Townsend L, Pollak T, Leite MI, Harrison PJ, Lennox BR, Okai D, Manohar SG, Irani SR. The psychopathology of NMDAR-antibody encephalitis in adults: a systematic review and phenotypic analysis of individual patient data. The lancet. Psychiatry. 2019 Mar:6(3):235-246. doi: 10.1016/S2215-0366(19)30001-X. Epub 2019 Feb 11 [PubMed PMID: 30765329]

Level 1 (high-level) evidence

[7]

Titulaer MJ, McCracken L, Gabilondo I, Armangué T, Glaser C, Iizuka T, Honig LS, Benseler SM, Kawachi I, Martinez-Hernandez E, Aguilar E, Gresa-Arribas N, Ryan-Florance N, Torrents A, Saiz A, Rosenfeld MR, Balice-Gordon R, Graus F, Dalmau J. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. The Lancet. Neurology. 2013 Feb:12(2):157-65. doi: 10.1016/S1474-4422(12)70310-1. Epub 2013 Jan 3 [PubMed PMID: 23290630]

Level 2 (mid-level) evidence

[8]

Ariño H, Armangué T, Petit-Pedrol M, Sabater L, Martinez-Hernandez E, Hara M, Lancaster E, Saiz A, Dalmau J, Graus F. Anti-LGI1-associated cognitive impairment: Presentation and long-term outcome. Neurology. 2016 Aug 23:87(8):759-65. doi: 10.1212/WNL.0000000000003009. Epub 2016 Jul 27 [PubMed PMID: 27466467]

[9]

van Sonderen A, Thijs RD, Coenders EC, Jiskoot LC, Sanchez E, de Bruijn MA, van Coevorden-Hameete MH, Wirtz PW, Schreurs MW, Sillevis Smitt PA, Titulaer MJ. Anti-LGI1 encephalitis: Clinical syndrome and long-term follow-up. Neurology. 2016 Oct 4:87(14):1449-1456 [PubMed PMID: 27590293]

[10]

van Sonderen A, Ariño H, Petit-Pedrol M, Leypoldt F, Körtvélyessy P, Wandinger KP, Lancaster E, Wirtz PW, Schreurs MW, Sillevis Smitt PA, Graus F, Dalmau J, Titulaer MJ. The clinical spectrum of Caspr2 antibody-associated disease. Neurology. 2016 Aug 2:87(5):521-8. doi: 10.1212/WNL.0000000000002917. Epub 2016 Jul 1 [PubMed PMID: 27371488]

[11]

Irani SR, Pettingill P, Kleopa KA, Schiza N, Waters P, Mazia C, Zuliani L, Watanabe O, Lang B, Buckley C, Vincent A. Morvan syndrome: clinical and serological observations in 29 cases. Annals of neurology. 2012 Aug:72(2):241-55. doi: 10.1002/ana.23577. Epub 2012 Apr 4 [PubMed PMID: 22473710]

Level 3 (low-level) evidence

[12]

Spatola M, Petit-Pedrol M, Simabukuro MM, Armangue T, Castro FJ, Barcelo Artigues MI, Julià Benique MR, Benson L, Gorman M, Felipe A, Caparó Oblitas RL, Rosenfeld MR, Graus F, Dalmau J. Investigations in GABA(A) receptor antibody-associated encephalitis. Neurology. 2017 Mar 14:88(11):1012-1020. doi: 10.1212/WNL.0000000000003713. Epub 2017 Feb 15 [PubMed PMID: 28202703]

[13]

Petit-Pedrol M, Armangue T, Peng X, Bataller L, Cellucci T, Davis R, McCracken L, Martinez-Hernandez E, Mason WP, Kruer MC, Ritacco DG, Grisold W, Meaney BF, Alcalá C, Sillevis-Smitt P, Titulaer MJ, Balice-Gordon R, Graus F, Dalmau J. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. The Lancet. Neurology. 2014 Mar:13(3):276-86. doi: 10.1016/S1474-4422(13)70299-0. Epub 2014 Jan 22 [PubMed PMID: 24462240]

Level 3 (low-level) evidence

[14]

Lancaster E, Lai M, Peng X, Hughes E, Constantinescu R, Raizer J, Friedman D, Skeen MB, Grisold W, Kimura A, Ohta K, Iizuka T, Guzman M, Graus F, Moss SJ, Balice-Gordon R, Dalmau J. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. The Lancet. Neurology. 2010 Jan:9(1):67-76. doi: 10.1016/S1474-4422(09)70324-2. Epub 2009 Dec 2 [PubMed PMID: 19962348]

Level 3 (low-level) evidence

[15]

Laurido-Soto O, Brier MR, Simon LE, McCullough A, Bucelli RC, Day GS. Patient characteristics and outcome associations in AMPA receptor encephalitis. Journal of neurology. 2019 Feb:266(2):450-460. doi: 10.1007/s00415-018-9153-8. Epub 2018 Dec 17 [PubMed PMID: 30560455]

[16]

Tobin WO, Lennon VA, Komorowski L, Probst C, Clardy SL, Aksamit AJ, Appendino JP, Lucchinetti CF, Matsumoto JY, Pittock SJ, Sandroni P, Tippmann-Peikert M, Wirrell EC, McKeon A. DPPX potassium channel antibody: frequency, clinical accompaniments, and outcomes in 20 patients. Neurology. 2014 Nov 11:83(20):1797-803. doi: 10.1212/WNL.0000000000000991. Epub 2014 Oct 15 [PubMed PMID: 25320100]

[17]

Carvajal-González A, Leite MI, Waters P, Woodhall M, Coutinho E, Balint B, Lang B, Pettingill P, Carr A, Sheerin UM, Press R, Press R, Lunn MP, Lim M, Maddison P, Meinck HM, Vandenberghe W, Vincent A. Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. Brain : a journal of neurology. 2014 Aug:137(Pt 8):2178-92. doi: 10.1093/brain/awu142. Epub 2014 Jun 20 [PubMed PMID: 24951641]

Level 3 (low-level) evidence

[18]

Hamid SHM, Whittam D, Saviour M, Alorainy A, Mutch K, Linaker S, Solomon T, Bhojak M, Woodhall M, Waters P, Appleton R, Duddy M, Jacob A. Seizures and Encephalitis in Myelin Oligodendrocyte Glycoprotein IgG Disease vs Aquaporin 4 IgG Disease. JAMA neurology. 2018 Jan 1:75(1):65-71. doi: 10.1001/jamaneurol.2017.3196. Epub [PubMed PMID: 29131884]

[19]

Gresa-Arribas N, Planagumà J, Petit-Pedrol M, Kawachi I, Katada S, Glaser CA, Simabukuro MM, Armangué T, Martínez-Hernández E, Graus F, Dalmau J. Human neurexin-3α antibodies associate with encephalitis and alter synapse development. Neurology. 2016 Jun 14:86(24):2235-42. doi: 10.1212/WNL.0000000000002775. Epub 2016 May 11 [PubMed PMID: 27170573]

[20]

Gaig C, Compta Y. Neurological profiles beyond the sleep disorder in patients with anti-IgLON5 disease. Current opinion in neurology. 2019 Jun:32(3):493-499. doi: 10.1097/WCO.0000000000000677. Epub [PubMed PMID: 30694925]

Level 3 (low-level) evidence

[21]

Cheng Z, Song Y, Zhao S, Sui X, Xie L, Zhao H, Pan X, Cui L, Huang X, Ma S. Anti-GluK2 antibody-positive autoimmune encephalitis concurrent with multiple myeloma: a case report. BMC neurology. 2025 Jan 20:25(1):27. doi: 10.1186/s12883-025-04037-3. Epub 2025 Jan 20 [PubMed PMID: 39833741]

Level 3 (low-level) evidence

[22]

Landa J, Guasp M, Míguez-Cabello F, Guimarães J, Mishima T, Oda F, Zipp F, Krajinovic V, Fuhr P, Honnorat J, Titulaer M, Simabukuro M, Planagumà J, Martínez-Hernández E, Armangué T, Saiz A, Gasull X, Soto D, Graus F, Sabater L, Dalmau J, GluK2 encephalitis study group. Encephalitis with Autoantibodies against the Glutamate Kainate Receptors GluK2. Annals of neurology. 2021 Jul:90(1):101-117. doi: 10.1002/ana.26098. Epub 2021 May 17 [PubMed PMID: 33949707]

[23]

Ni P, Bai L, Jiang N, Fan S, Yao M, Ren H, Guan H. Case Report: Anti-ADAM23 antibody: an overlooked autoantibody against VGKC-complex in autoimmune encephalitis. Frontiers in immunology. 2025:16():1589360. doi: 10.3389/fimmu.2025.1589360. Epub 2025 May 30 [PubMed PMID: 40519920]

Level 3 (low-level) evidence

[24]

Dalmau J, Graus F. Antibody-Mediated Encephalitis. The New England journal of medicine. 2018 Mar 1:378(9):840-851. doi: 10.1056/NEJMra1708712. Epub [PubMed PMID: 29490181]

[25]

Gravier-Dumonceau A, Ameli R, Rogemond V, Ruiz A, Joubert B, Muñiz-Castrillo S, Vogrig A, Picard G, Ambati A, Benaiteau M, Rulquin F, Ciron J, Deiva K, de Broucker T, Kremer L, Kerschen P, Sellal F, Bouldoires B, Genet R, Biberon J, Bigot A, Duval F, Issa N, Rusu EC, Goudot M, Dutray A, Devoize JL, Hopes L, Kaminsky AL, Philbert M, Chanson E, Leblanc A, Morvan E, Andriuta D, Diraison P, Mirebeau G, Derollez C, Bourg V, Bodard Q, Fort C, Grigorashvili-Coin I, Rieul G, Molinier-Tiganas D, Bonnan M, Tchoumi T, Honnorat J, Marignier R. Glial Fibrillary Acidic Protein Autoimmunity: A French Cohort Study. Neurology. 2022 Feb 8:98(6):e653-e668. doi: 10.1212/WNL.0000000000013087. Epub 2021 Nov 19 [PubMed PMID: 34799461]

[26]

Hagbohm C, Ouellette R, Flanagan EP, Jonsson DI, Piehl F, Banwell B, Wickström R, Iacobaeus E, Granberg T, Ineichen BV. Clinical and neuroimaging phenotypes of autoimmune glial fibrillary acidic protein astrocytopathy: A systematic review and meta-analysis. European journal of neurology. 2024 Jul:31(7):e16284. doi: 10.1111/ene.16284. Epub 2024 Mar 20 [PubMed PMID: 38506182]

Level 1 (high-level) evidence

[27]

Lin Y, Diao Z, Low J, Wang A, Wu W, Cao L. Therapeutic efficacy of telitacicept in a patient with GFAP autoimmune astrocytopathy: a case report. Frontiers in immunology. 2025:16():1691029. doi: 10.3389/fimmu.2025.1691029. Epub 2025 Oct 16 [PubMed PMID: 41181139]

Level 3 (low-level) evidence

[28]

Zhang W, Xie Y, Wang Y, Liu F, Wang L, Lian Y, Liu H, Wang C, Xie N. Clinical characteristics and prognostic factors for short-term outcomes of autoimmune glial fibrillary acidic protein astrocytopathy: a retrospective analysis of 33 patients. Frontiers in immunology. 2023:14():1136955. doi: 10.3389/fimmu.2023.1136955. Epub 2023 Jun 7 [PubMed PMID: 37350972]

Level 2 (mid-level) evidence

[29]

Restrepo-Martínez M, Espinola-Nadurille M, López-Hernández JC, Martínez V, Téllez-Martínez JA, Bustamante-Gómez PA, Bautista-Gómez P, Bayliss L, Ramírez-Bermúdez J. [Neuropsychiatric aspects of anti-NMDA receptor encephalitis]. Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993). 2021 Oct-Dec:68(4):251-263. doi: 10.29262/ram.v68i4.953. Epub [PubMed PMID: 34904561]

[30]

Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, Cortese I, Dale RC, Gelfand JM, Geschwind M, Glaser CA, Honnorat J, Höftberger R, Iizuka T, Irani SR, Lancaster E, Leypoldt F, Prüss H, Rae-Grant A, Reindl M, Rosenfeld MR, Rostásy K, Saiz A, Venkatesan A, Vincent A, Wandinger KP, Waters P, Dalmau J. A clinical approach to diagnosis of autoimmune encephalitis. The Lancet. Neurology. 2016 Apr:15(4):391-404. doi: 10.1016/S1474-4422(15)00401-9. Epub 2016 Feb 20 [PubMed PMID: 26906964]

[31]

Kerstens J, Schreurs MWJ, de Vries JM, Neuteboom RF, Brenner J, Crijnen YS, van Steenhoven RW, de Bruijn MAAM, van Sonderen A, van Coevorden-Hameete MH, Bastiaansen AEM, Vermeiren MR, Damoiseaux JGMC, Otten HG, Frijns CJM, Meek B, Platteel ACM, van de Mortel A, Delnooz CCS, Broeren MAC, Verbeek MM, Hoff EI, Boukhrissi S, Franken SC, Nagtzaam MMP, Paunovic M, Veenbergen S, Sillevis Smitt PAE, Titulaer MJ. Autoimmune Encephalitis and Paraneoplastic Neurologic Syndromes: A Nationwide Study on Epidemiology and Antibody Testing Performance. Neurology(R) neuroimmunology & neuroinflammation. 2024 Nov:11(6):e200318. doi: 10.1212/NXI.0000000000200318. Epub 2024 Oct 28 [PubMed PMID: 39467237]

[32]

Abboud H, Probasco JC, Irani S, Ances B, Benavides DR, Bradshaw M, Christo PP, Dale RC, Fernandez-Fournier M, Flanagan EP, Gadoth A, George P, Grebenciucova E, Jammoul A, Lee ST, Li Y, Matiello M, Morse AM, Rae-Grant A, Rojas G, Rossman I, Schmitt S, Venkatesan A, Vernino S, Pittock SJ, Titulaer MJ, Autoimmune Encephalitis Alliance Clinicians Network. Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management. Journal of neurology, neurosurgery, and psychiatry. 2021 Jul:92(7):757-768. doi: 10.1136/jnnp-2020-325300. Epub 2021 Mar 1 [PubMed PMID: 33649022]

[33]

Yang JH, Liu EN, Nguyen L, Dunn-Pirio A, Graves JS. Survival Analysis of Immunotherapy Effects on Relapse Rate in Pediatric and Adult Autoimmune Encephalitis. Neurology. 2023 Nov 27:101(22):e2300-e2313. doi: 10.1212/WNL.0000000000207746. Epub 2023 Nov 27 [PubMed PMID: 37827848]

[34]

Abboud H, Probasco J, Irani SR, Ances B, Benavides DR, Bradshaw M, Christo PP, Dale RC, Fernandez-Fournier M, Flanagan EP, Gadoth A, George P, Grebenciucova E, Jammoul A, Lee ST, Li Y, Matiello M, Morse AM, Rae-Grant A, Rojas G, Rossman I, Schmitt S, Venkatesan A, Vernino S, Pittock SJ, Titulaer M, Autoimmune Encephalitis Alliance Clinicians Network. Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management. Journal of neurology, neurosurgery, and psychiatry. 2021 Mar 1:92(8):897-907. doi: 10.1136/jnnp-2020-325302. Epub 2021 Mar 1 [PubMed PMID: 33649021]

[35]

Nosadini M, Eyre M, Molteni E, Thomas T, Irani SR, Dalmau J, Dale RC, Lim M, International NMDAR Antibody Encephalitis Consensus Group, Anlar B, Armangue T, Benseler S, Cellucci T, Deiva K, Gallentine W, Gombolay G, Gorman MP, Hacohen Y, Jiang Y, Lim BC, Muscal E, Ndondo A, Neuteboom R, Rostásy K, Sakuma H, Sartori S, Sharma S, Tenembaum SN, Van Mater HA, Wells E, Wickstrom R, Yeshokumar AK. Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephalitis: A Meta-analysis. JAMA neurology. 2021 Nov 1:78(11):1333-1344. doi: 10.1001/jamaneurol.2021.3188. Epub [PubMed PMID: 34542573]

Level 1 (high-level) evidence

[36]

Thaler FS, Zimmermann L, Kammermeier S, Strippel C, Ringelstein M, Kraft A, Sühs KW, Wickel J, Geis C, Markewitz R, Urbanek C, Sommer C, Doppler K, Penner L, Lewerenz J, Rößling R, Finke C, Prüss H, Melzer N, Wandinger KP, Leypoldt F, Kümpfel T, German Network for Research on Autoimmune Encephalitis (GENERATE). Rituximab Treatment and Long-term Outcome of Patients With Autoimmune Encephalitis: Real-world Evidence From the GENERATE Registry. Neurology(R) neuroimmunology & neuroinflammation. 2021 Nov:8(6):. doi: 10.1212/NXI.0000000000001088. Epub 2021 Oct 1 [PubMed PMID: 34599001]

[37]

Dalmau J, Armangué T, Planagumà J, Radosevic M, Mannara F, Leypoldt F, Geis C, Lancaster E, Titulaer MJ, Rosenfeld MR, Graus F. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. The Lancet. Neurology. 2019 Nov:18(11):1045-1057. doi: 10.1016/S1474-4422(19)30244-3. Epub 2019 Jul 17 [PubMed PMID: 31326280]

[38]

Dinoto A, Ferrari S, Mariotto S. Treatment Options in Refractory Autoimmune Encephalitis. CNS drugs. 2022 Sep:36(9):919-931. doi: 10.1007/s40263-022-00943-z. Epub 2022 Aug 2 [PubMed PMID: 35917105]

[39]

Smets I, Titulaer MJ. Antibody Therapies in Autoimmune Encephalitis. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 2022 Apr:19(3):823-831. doi: 10.1007/s13311-021-01178-4. Epub 2022 Jan 20 [PubMed PMID: 35060089]

[40]

Berkowitz AL. Approach to Neurologic Infections. Continuum (Minneapolis, Minn.). 2021 Aug 1:27(4):818-835. doi: 10.1212/CON.0000000000000984. Epub [PubMed PMID: 34623094]

[41]

Brenner J, Ruhe CJ, Kulderij I, Bastiaansen AEM, Crijnen YS, Kret CN, Verkoelen JCP, Tolido AAG, Thomassen B, Kersten LP, de Bruijn MAAM, Olijslagers SHC, Mandarakas MR, Kerstens J, van Steenhoven RW, de Vries JM, Veenbergen S, Schreurs MWJ, Neuteboom RF, Sillevis Smitt PAE, van den Berg E, Titulaer MJ. Long-Term Cognitive, Functional, and Patient-Reported Outcomes in Patients With Anti-NMDAR Encephalitis. Neurology. 2024 Dec 24:103(12):e210109. doi: 10.1212/WNL.0000000000210109. Epub 2024 Nov 20 [PubMed PMID: 39566012]

[42]

Heine J, Kopp UA, Klag J, Ploner CJ, Prüss H, Finke C. Long-Term Cognitive Outcome in Anti-N-Methyl-D-Aspartate Receptor Encephalitis. Annals of neurology. 2021 Dec:90(6):949-961. doi: 10.1002/ana.26241. Epub 2021 Oct 21 [PubMed PMID: 34595771]

[43]

Guasp M, Rosa-Justicia M, Muñoz-Lopetegi A, Martínez-Hernández E, Armangué T, Sugranyes G, Stein H, Borràs R, Prades L, Ariño H, Planagumà J, De-La-Serna E, Escudero D, Llufriu S, Sánchez-Valle R, Santamaria J, Compte A, Castro-Fornieles J, Dalmau J, Spanish anti-NMDAR Encephalitis Study Group. Clinical characterisation of patients in the post-acute stage of anti-NMDA receptor encephalitis: a prospective cohort study and comparison with patients with schizophrenia spectrum disorders. The Lancet. Neurology. 2022 Oct:21(10):899-910. doi: 10.1016/S1474-4422(22)00299-X. Epub [PubMed PMID: 36115362]

[44]

Morgan A, Li Y, Thompson NR, Milinovich A, Abbatemarco JR, Cohen JA, Ontaneda D, Punia V, Rae-Grant A, Galioto R, Kunchok A. Longitudinal Disability, Cognitive Impairment, and Mood Symptoms in Patients With Anti-NMDA Receptor Encephalitis. Neurology. 2024 Feb 27:102(4):e208019. doi: 10.1212/WNL.0000000000208019. Epub 2024 Jan 24 [PubMed PMID: 38266213]

[45]

Xu Q, Wang Q, Han J, Mao F, Zeng S, Chen S, Zhao C, Gu M, Li Z, Fu X, Luo X, Huang Y. Central Hypoventilation Is a Key Risk Factor for Mechanical Ventilation During the Acute Phase of Anti-N-Methyl-D-Aspartate Receptor Encephalitis. Frontiers in neurology. 2021:12():728594. doi: 10.3389/fneur.2021.728594. Epub 2021 Nov 2 [PubMed PMID: 34795627]